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Abstract
Organochlorine insecticides have been studied extensively in relation to breast cancer incidence 
and results from two meta-analyses have been null for late-life residues, possibly due to 
measurement error. Whether these compounds influence survival remains to be fully explored. We 
examined associations between organochlorine insecticides (p,p’-DDT, its primary metabolite, 
p,p’-DDE, and chlordane) assessed shortly after diagnosis and survival among women with breast 
cancer. A population-based sample of women diagnosed with a first primary invasive or in situ 
breast cancer in 1996–1997 and with available organochlorine blood measures (n=633) were 
followed for vital status through 2011. After follow-up of 5 and 15 years, we identified 55 and 189 
deaths, of which 36 and 74, respectively, were breast cancer-related. Using Cox regression 
models, we estimated the multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals 
(CIs) for lipid-adjusted organochlorine concentrations with all-cause and breast cancer-specific 
mortality. At 5 years after diagnosis, the highest tertile of DDT concentration was associated with 
all-cause (HR=2.19; 95%CI: 1.02, 4.67) and breast cancer-specific (HR=2.72; 95%CI: 1.04, 7.13) 
mortality. At 15 years, middle tertile concentrations of DDT (HR=1.42; CI 0.99, 2.06) and 
chlordane (HR=1.42; 95%CI: 0.94, 2.12) were modestly associated with all-cause and breast 
cancer-specific mortality. Third tertile DDE concentrations were inversely associated with 15-year 
all-cause mortality (HR=0.66; 95%CI: 0.44, 0.99). This is the first population-based study in the 
United States to show that DDT may adversely impact survival following breast cancer diagnosis. 
Further studies are warranted given the high breast cancer burden and the ubiquity of these 
chemicals.
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INTRODUCTION
In the United States (US), the organochlorine insecticide dichlorodiphenyltrichloroethane 
(DDT) was first used during World War II to combat malaria, typhus, and other diseases 
among military populations.1 Widespread use began shortly after in 1945. DDT use 
increased until 1959 and declined steadily until its ban in 1972 because of growing 
environmental and wildlife concerns.2,3 Other countries restricted its use several years 
earlier, including Canada in 1969, while others continued to use DDT until much later, 
including Mexico which halted the use of DDT in 2000.2,4 Today, DDT production 
continues in China, India, and North Korea, as does indoor residual spraying for malaria 
control, which involves coating the walls and other surfaces of a house with a residual 
insecticide,5 in countries such as India, Ethiopia, and South Africa.6 Continued DDT use 
ensures continued direct and indirect exposure to DDT and its metabolites.7 Another 
organochlorine insecticide, chlordane, was used agriculturally in the US from 1948 until 
1983 and then restricted to use for termite control until its ban in 1988.8
DDT and its primary metabolite, dichlorodiphenyldichloroethylene (DDE), have been 
extensively studied in relation to breast cancer incidence because they are highly lipophilic 
and have long biological half-lives.9,10 While DDT shows estrogenic activity in breast cells 
in vitro,11 DDE is an anti-androgen.11–13 Furthermore, organochlorine chemicals are stored 
in adipose tissue, including the breast.14 Importantly, breast tissue levels can be estimated 
validly and less invasively with peripheral blood measures.15 Additionally, it is important to 
consider weight and weight change since body mass index (BMI), a surrogate for adiposity, 
can alter tissue and blood concentrations and can cause slower elimination of organochlorine 
compounds and thus result in extended exposures in the body.10 While several studies have 
found significant associations between DDT, DDE, and chlordane and breast cancer 
incidence,16–21 results of most,22–27 including two meta-analyses,28,29 have largely been 
null, possibly because the measurements obtained may not correctly reflect the exposures 
during the etiologically relevant period(s). Although data on early life exposures are limited, 
results of a two-generation cohort studies found that blood measures of DDT ascertained 
prenatally or prior to a woman's reproductive years were associated with subsequent risk of 
developing breast cancer;21,30,31 however, the role of early life exposures to DDT remains 
unresolved.32
Whether organochlorine pesticides impact breast cancer survival remains a largely 
unexplored topic, with only one research group in Denmark publishing a positive association 
between the organochlorine insecticide dieldrin and all-cause and breast cancer-specific 
mortality following a breast cancer diagnosis.33–35 This potential association is particularly 
important given the high breast cancer incidence and mortality among women in the US and 
globally.36,37
Parada et al. Page 2













The present study aimed to examine the associations of the organochlorine insecticides, 
DDT and chlordane, and the DDT metabolite DDE with survival among US women with 
breast cancer. We hypothesized that organochlorine compounds would be positively 
associated with mortality, particularly breast cancer-specific mortality. Additionally, we 
were interested in examining whether weight-related measures modified the relationships 
observed given the potential for adiposity to alter the elimination rate of organochlorine 
compounds.10
METHODS
Study design and study population
The Long Island Breast Cancer Study Project (LIBCSP) was a population-based study that 
was initiated as a case-control study to identify environmental factors associated with 
developing breast cancer, and then continued as a follow-up study to identify factors 
associated with survival. Details of the LIBCSP have been published previously.24,38 
Briefly, adult female residents of Nassau and Suffolk counties with a first diagnosis of 
invasive or in situ breast cancer between August 1, 1996, and July 31, 1997, confirmed by 
physicians and medical records, were identified for inclusion through daily/weekly contact 
of pathology departments of 31 hospitals on Long Island and New York City, NY.
At baseline, on average within three months of the participant’s diagnosis, 1,508 women 
with breast cancer, with signed informed consent, completed an interviewer-administered 
questionnaire; 1,102 provided blood samples for laboratory analyses. The present study uses 
data from 633 women with breast cancer for whom blood levels of DDT (n=622), DDE 
(n=632), or chlordane (n=586) and lipids were available.24 Participants with available 
organochlorine measures were primarily white (92%) with a mean age of 58 years 
(range=29–89 years), post-menopausal (66%), and diagnosed with a first primary invasive 
breast cancer (71%), as described in Table 1.
The LIBCSP study protocol was approved by the Institutional Review Board of all 
participating institutions and in accordance with an assurance filed with and approved by the 
US Department of Health and Human Services.
Laboratory assays
Blood sample collection, analytic methods, and QA/QC procedures in the LIBCSP have 
been previously published.10,38 Briefly, approximately 73% of participants provided 40-mL 
non-fasting blood samples, of which 77% were collected prior to the initiation of 
chemotherapy. Samples for assaying were selected as follows: (1) randomly sampled from 
among women with invasive breast cancer (n=415); (2) all women with tumors initially 
categorized as in situ that were subsequently determined to be invasive (n=42); (3) all 
women with in situ tumors (n=184); and (4) all African-American participants who were not 
selected in the first three steps (n=5).
Gas chromatography/electron capture detection was conducted as outlined by Brock et al.39 
to estimate concentrations of p,p’-DDT (DDT), p,p’-DDE (DDE) and chlordane (the sum of 
oxychlordane and trans-nonachlor). Positive and zero values of individual organochlorine 
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levels below the detection limit (0.2ng/ml) were set to the lowest observed positive value for 
that compound, rather than being assigned a censored value. The proportions of observations 
that were below the detection limit were 8% for DDT, 1% for DDE, and 8% for chlordane.
Lipid profiles were determined for use in adjustment of DDT/DDE concentrations to 
account for non-fasting variations and to more closely approximate adipose tissue 
levels.40,41 We also present results for models in which we include total lipids as a covariate 
(Table S1). In the main analyses, continuous concentrations of lipid-adjusted 
organochlorines were divided into tertiles using the following cut-points (in ng/g) for: p,p’-
DDT, <56.82, ≥56.82–<91.22 and ≥91.22; p,p’-DDE, <467.86, ≥467.86–<1,058.20 and 
≥1,058.20; and chlordane, <81.08, ≥81.08–<131.00, and ≥131.00.
Follow-up for mortality
The National Death Index (NDI), a centralized database of death record information 
maintained by the National Center for Health Statistics,42 was used to ascertain date and 
cause of death. International Statistical Classification of Diseases codes 174.9 and C-50.9 
listed anywhere on the death certificate were used to identify breast cancer-related deaths. 
Participants were followed from diagnosis in 1996–1997 until December 31, 2011. The 
maximum duration of follow-up was 15.42 years. Among our 633 participants after 5-years 
of follow-up, 55 (9%) deaths occurred, of which 36 were due to breast cancer; and, after 15 
years, 189 (30%) deaths occurred, with 74 due to breast cancer.
Interview and medical record data
Prior to data collection, participants provided signed informed consent and permission for 
medical record release. Participants completed a 2-hour interviewer-administered 
questionnaire to assess demographic characteristics and potential and established risk/
prognostic factors for breast cancer. Medical records were abstracted to obtain information 
on tumor hormone receptor status, primarily estrogen and progesterone receptor (ER and 
PR, respectively) status and first course of treatment.
Statistical analyses
Kaplan-Meier survival curves were used for preliminary examination of the unadjusted data 
(Figure 1). The proportional hazards assumption was assessed by testing interaction terms of 
the exposure variables with time and natural log of time and by Schoenfeld residuals for all 
covariates. No violations of the proportional hazards assumption were evident based on 
these tests; however, several of the p-values for the interaction terms of the exposure 
variables with time at 15 years were marginally significant for all-cause 
[log(time)*log(DDT) p=0.07] and breast cancer-specific [log(time)*log(DDT) p=0.09; 
log(time)*log(DDE) p=0.12] mortality. Multivariable Cox models43 were fit to estimate 
hazard ratios (HRs) and 95% confidence intervals (CIs) for increasing tertiles of lipid-
adjusted DDT, DDE, and chlordane concentrations in association with all-cause and breast 
cancer-specific mortality at 5 and 15 years after diagnosis. Models were re-run restricted to 
cases with invasive tumors. Tests for trend used continuous natural log-transformed lipid-
adjusted concentrations in regression models.
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To assess for effect modification interaction terms between continuous organochlorine 
concentrations and body size were included in Cox models. Additionally, models were 
stratified by: (1) body mass index (BMI; weight (kg)/height (m)2), in the year prior to 
diagnosis, categorized as “BMI<25kg/m2” and “BMI≥25kg/m2;” and (2) percent weight-
gain since age 20, categorized as “0–<20% weight-gain”, “20–<40% weight-gain” and 
“≥40% weight-gain” 44. Few women reported a decrease in adult weight change; therefore, 
associations within the strata of weight-loss were not examined. Also, at 5 years after 
diagnosis there were too few deaths to examine the associations stratified by body size; 
therefore, only 15-year associations are presented.
Possible confounders were selected based on previous studies of organochlorines and breast 
cancer incidence and survival10,45 and directed acyclic graphs,46 and included: age at 
diagnosis (5-year age groups), parity/lactation (nulliparous, parous/never lactated, and 
parous/ever lactated); menopausal status (premenopausal and postmenopausal), hormone 
replacement therapy use (continuous, number of months of use), BMI (continuous); annual 
household income (categorical); cigarette smoking (never, former, and current smokers).
Hormone receptor status was not included as a covariate in the models since ER/PR status 
may mediate the association between organochlorine compounds and breast cancer 
survival47 precluding adjustment by stratification for receptor status.48 Treatment undergone 
was also not included in our models as a covariate, given treatment is also a possible causal 
intermediate since ER/PR status is directly related to treatment.49
All statistical analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, 
NC).
RESULTS
5-year all-cause and breast cancer-specific mortality
In the Kaplan-Meier survival curves, compared to tertile 1, tertiles 2 and 3 of DDT were 
associated with a higher probability of 5-year all-cause and breast cancer-specific mortality 
(Figure 1, Panels A and D). As shown in Table 2, multivariable-adjusted HRs for 5-year 
all-cause mortality were more than doubled for women with DDT concentrations in the 
middle (HR=2.55, 95%CI: 1.20, 5.45) and highest (HR=2.19, 95%CI: 1.02, 4.67)) tertiles, 
as compared to women with DDT concentrations in the lowest tertile (p-trend=0.02). The 
magnitude appeared modestly larger for the corresponding DDT estimates for 5-year breast 
cancer-specific mortality (HR=2.94; 95%CI: 1.12, 7.67; HR=2.72; 95%CI: 1.04, 7.13, 
respectively; p-trend=0.02). Estimates were slightly more pronounced when we restricted 
our analyses to women diagnosed with invasive breast cancer (Table S2) and post-
menopausal women (Table S3). Additionally, these estimates were relatively unchanged 
when BMI was excluded from the adjustment set (Table S4).
In the Kaplan-Meier survival curves, the highest tertiles of DDE and chlordane did not 
appear to be associated with higher 5-year all-cause and breast cancer specific mortality 
(Figure 1, Panels B, C, E, and F). However, in the multivariable models associations with 
all-cause and breast cancer-specific mortality 5 years after breast cancer diagnosis were 
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positively associated with chlordane, and inversely associated with DDE, but the confidence 
intervals for the modest hazards included the null value.
15-year all-cause and breast cancer-specific mortality
In the Kaplan-Meier curves, the DDT survival curves for all-cause mortality appeared to 
converge after 8 years while the survival curves for chlordane after 5 years diverged. In the 
multivariable models, as shown in Table 2, 15-year all-cause mortality hazards were 
elevated for DDT (HR=1.42, 95%CI: 0.99, 2.06) and chlordane (HR=1.42, 95%CI: 0.94, 
2.12) concentrations in the middle tertiles. The highest tertile of chlordane was elevated 
though closer to the null (HR=1.31; 95%CI 0.86, 2.00). Corresponding 15-year hazards for 
breast cancer-specific mortality were similarly elevated for DDT (HR=1.59, 95%CI: 0.90, 
2.83) and chlordane (HR=1.47; 95%CI: 0.81, 2.67). In contrast, 15-year all-cause and breast 
cancer-specific mortality risk decreased with increasing DDE concentrations (p-trend=0.10). 
Most confidence intervals, however, included the null value. These inverse associations 
were not apparent for all-cause mortality in the Kaplan-Meier curves; however, the inverse 
association was apparent after 8 years for breast cancer-specific mortality (Figure 1, Panels 
A and E)
BMI-stratified 15-year all-cause mortality
As shown in Table 3, among women with BMI<25kg/m2, but not among women with 
BMI≥25kg/m2, hazards for all-cause mortality were increased in association with: DDT 
concentrations in the middle (HR=2.32; 95%CI: 1.23, 4.38) and highest (HR=1.43; 95%CI: 
0.73, 2.79) tertiles (p-interaction=0.03; p-trend=0.19); and with chlordane concentrations in 
the middle (HR=1.79; 95%CI: 0.92, 3.47) and highest (HR=1.42; 95%CI: 0.69, 2.92) tertiles 
(p-interaction<0.01; p-trend=0.27). In contrast, within both strata of categorized BMI, 
increasing DDE concentrations were associated with decreasing hazard of all-cause 
mortality, but estimates were strongest among women with BMI<25kg/m2 (p-
interaction=0.09).
BMI-stratified 15-year breast cancer-specific mortality
As shown in Table 3, hazards for breast cancer-specific mortality 15 years after diagnosis 
were increased among women with BMI<25kg/m2 for: DDT concentrations in the middle 
(HR=1.92; 95%CI: 0.76, 4.88) and highest (HR=1.46; 95%CI: 0.55, 3.89) tertiles (p-
interaction<0.01; p-trend=0.56); and chlordane concentrations in the middle (HR=2.93; 
95%CI: 1.10, 7.79) and highest (HR=1.72; 95%CI: 0.54, 5.48) tertiles (p-interaction=0.82; 
p-trend=0.57). In contrast, among women with BMI<25kg/m2, but not among women with 
BMI≥25kg/m2, breast cancer-specific mortality was reduced in association with the middle 
(HR=0.82; 95%CI: 0.34, 1.99) and highest (HR=0.23; 95%CI: 0.05, 1.09) DDE tertiles, but 
confidence intervals included the null value (p-interaction=0.14; p-trend=0.18).
Adult-lifetime percent weight gain-stratified 15-year all-cause mortality
As shown in Table 4, among women with 0–<20% lifetime weight-gain, 15-year all-cause 
mortality was positively associated with DDT concentrations in the middle tertile (HR=2.11; 
95%CI: 1.03, 4.32). The DDT-mortality association decreased in magnitude with increasing 
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percent weight gain for concentrations in the middle tertile (20–<40% weight gain, 
HR=1.30; 95%CI: 0.67, 2.51; ≥40% weight gain, HR=1.11; 95%CI: 0.54, 2.25; p-
interaction=0.25).
A similar pattern was observed for chlordane concentrations, where 15-year all-cause 
mortality was positively associated with middle tertile levels among women with 0–<20% 
lifetime weight-gain (HR=1.55; 95%CI: 0.70, 3.41) and a decrease in magnitude with 
increasing percent weight gain was observed (20–<40% weight gain HR=1.34; 95%CI: 0.69, 
2.60; ≥40% weight-gain HR=1.17; 95%CI: 0.50, 2.75; p-interaction=0.65).
In contrast, DDE concentrations were inversely associated with 15-year all-cause mortality 
among women with 20–<40% adult-lifetime percent weight-gain (HR=0.71; 95%CI: 0.37, 
1.38; HR=0.49; 95%CI: 0.24, 0.99; p-interaction=0.84).
DISCUSSION
In this first US population-based study to examine the association between blood levels of 
organochlorine compounds and survival following breast cancer, we observed a greater than 
two-fold increase in all-cause and breast cancer-specific mortality after 5 years of follow-up 
in association with DDT concentrations measured within a few month of diagnosis. 
Estimates were more pronounced when we restricted our analysis to women with invasive 
breast cancer only. Slightly attenuated DDT HRs remained elevated after 15 years of follow-
up, but CIs were imprecise. The more pronounced association 5 years after breast cancer 
diagnosis, rather than after 15, may reflect susceptible women dying within 5 years. The risk 
of death from breast cancer within 5 years of diagnosis, while low (10%), decreases after 6–
8 years during which death from other causes increases.50
To date, only one research group in Denmark has published on the association between 
organochlorine compounds and breast cancer mortality.33–35 In their initial report 33, among 
the compounds examined in 195 Danish women only dieldrin was associated with increased 
all-cause and breast cancer-specific mortality. In the present study, we were unable to 
examine dieldrin due to insufficient number of cases with levels above detectable limits;24 
however, we were able to examine DDT, DDE and chlordane. In the Danish study, there 
was a suggestion of elevated mortality following breast cancer for p,p’-DDT, which is 
consistent with the results reported here. In contrast to the Danish study, we also observed 
an increased risk of all-cause mortality 15 years after a breast cancer diagnosis for 
chlordane, but a decreased risk for DDE despite the much lower concentrations of 
organochlorine compounds observed in this study. In the US, one study has examined 
whether organochlorine levels were associated with recurrence among women of Long 
Island, NY.51 In their study, the highest tertiles of total PCBs and the middle tertiles of DDE 
were positively associated with recurrence. However, their study was limited by the small 
case-control (n=224 women, 30 of which were diagnosed with a recurrence), hospital-based 
study design.
Although endocrine disrupting chemicals may act through multiple, complex, and unknown 
pathways, several biological mechanisms related to the estrogenic and hormone-antagonistic 
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potential of these compounds may explain the associations observed here. The first is that 
organochlorine compounds may directly affect tumor cell proliferation by interacting with 
important receptors.52 The second proposed mechanism is that estrogenic organochlorine 
compounds stored in breast adipose tissue adjacent to the breast carcinoma may affect the 
tumor microenvironment making it more estrogenic favoring cell proliferation among 
hormone receptor positive neoplasms.47 Our positive findings between the estrogenic 
compounds DDT and chlordane and mortality support these mechanisms. We also observed 
an inverse association between DDE, a known anti-androgen, and mortality.13
Our stratified results that women with lower BMI and less adult-lifetime weight gain had the 
highest HRs of all-cause mortality, may reflect the competing estrogenic effects associated 
with high BMI. Our observation may be analogous to the situation where the positive 
association between breast cancer incidence and hormone replacement is only evident 
among non-obese women.53 Third, organochlorines compounds with known endocrine 
disruption effects may also result in metabolic disruption54 leading to pre- and post-
diagnosis weight changes which may influence survival.44,55
At least two studies21,31 have shown that timing of exposure, especially during critical 
developmental windows, may be important for breast cancer etiology. Failure to account for 
exposure windows may partially explain the lack of association observed for breast cancer 
incidence. In contrast, for survival following breast cancer, the relevant windows of 
exposure to environmental contaminants, including continued endogenous exposure from 
the release of stored toxins, may extend from as early as 5 years before diagnosis56 through 
death.55 Thus, a possible explanation for our observation of stronger associations with 5-
year mortality, rather than 15-year mortality, may be that biomarker concentrations assessed 
at baseline are more likely to reflect the relevant exposure period influencing mortality 
closer to diagnosis, rather than the exposures that are likely to have changed over the 15-
year period of follow-up; although we were not able to assess how organochlorine levels 
changed over time as a result of ongoing low-level dietary exposure.57 However, it is also 
possible that exposures in early life may influence the characteristics of the tumor (e.g. 
receptor status, grade, lymph node involvement, and stage at diagnosis),34,47,58,59 which are 
known impact the effectiveness of chemotherapy, aggression of the cancer, and probability 
of survival. Approximately one-third (212 of 633) of the women included in our study were 
born in or after 1945 when DDT was widely introduced in the US. These women could have 
been potentially exposed to technical DDT in utero, a window of exposure that has been 
shown to be associated with breast cancer incidence.31 Additionally, almost half (295 of 
633) of the women in our study were of younger reproductive age, between the ages of 14 
and 25, during the years of DDT peak use in the US, from 1955 through 1962.
Our study has several strengths including biomarker assessments of organochlorine 
compounds in blood samples that were collected from a population-based sample of 
American women within a few months following diagnosis of their first primary breast 
cancers, who were then subsequently followed using the NDI, which provides high quality 
ascertainment of vital status. Nonetheless, this study has several limitations. While the 
largest HR of mortality was observed 5 years after breast cancer diagnosis, the low 
frequency of deaths at 5 years in our study population precluded us from examining whether 
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these associations varied by a priori covariates of interest or by other potentially important 
characteristics such as birth cohort, although even with larger numbers we would be unable 
to say with certainty that birth cohort directly corresponds to age of exposure.
Another potential study concern is that we adjusted for BMI, which may have resulted in 
model misspecification. A recent study suggests that organochlorines may influence the 
metabolic system, including weight.60 Given that weight is a strong predictor of breast 
cancer survival,44,55 BMI is a possible causal intermediate for the organochlorine-breast 
cancer survival association. Thus, we also fit Cox models excluding BMI as a covariate. 
However, removal of BMI from the model did not appreciably alter our HR estimates; any 
potential bias of our results due to inclusion of BMI in our models is likely to be low.
Our study included only one organochlorine measurement. While concentrations measured 
at baseline are likely to be more temporally relevant to the outcomes, we were unable to 
account for changes in exposure to organochlorine compounds. Additionally, the biomarker 
assessment does not provide any information about the source of exposure and whether 
women were exposed to technical DDT and chlordane or whether they were exposed 
through other sources such as diet. Although we considered associations stratified by weight 
gain, we were not able to fully account for changes in organochlorine concentrations over 
time due to BMI changes, which may result in changes in the amount of chemicals stored in 
fatty breast tissue.10
Finally, determination of breast cancer-related deaths may have resulted in outcome 
misclassification. However, this misclassification is likely to be non-differential with respect 
to organochlorine levels. This non-differential misclassification would attenuate the risk 
estimates for breast cancer-specific mortality.61
Results of this first US population-based study indicate that exposure to organochlorine 
insecticides, especially those with known estrogenic properties, may negatively impact 
survival following breast cancer. In our study, DDT was associated with a more than two-
fold increase in 5-year all-cause and breast-cancer specific mortality; and the mortality 
hazards, while attenuated, remained elevated 15 years after the first primary breast cancer 
diagnosis. Our finding that DDE was inversely associated with mortality may be suggestive 
of an anti-androgenic pathway that requires further investigation. Given the limited research 
on breast cancer survival conducted to date, our findings require replication in future studies, 
which should explore additional organochlorine compounds. Our study findings, which are 
consistent with the results from Denmark,35 emphasize the importance of environmental 
exposures in cancer survival and have important policy implications since further restriction 
of the use of these and other similar chemicals may be warranted due to the high burden of 
breast cancer worldwide.
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While organochlorine compounds have been extensively studied in relation to breast 
cancer incidence, only one research group to date has examined whether these 
compounds are associated with survival. In this first population-based study in the United 
States, we show that DDT may adversely impact survival following breast cancer 
diagnosis. These results emphasize the importance of environmental exposures in cancer 
survival.
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Kaplan-Meier survival curves for all-cause mortality for (A) p,p’-DDT, (B) p,p’-DDE, and 
(C) chlordane and for breast cancer-specific mortality for (D) p,p’-DDT, (E) p,p’-DDE, and 
(F) chlordane stratified by organochlorine concentration tertiles 1 (solid line), 2 (dotted 
line), and 3 (dashed line) among LIBCSP women diagnosed with breast cancer in 1996–
1997 (n=633). The x-axis shows times to death in years; the y-axis shows proportion of 
participants alive.
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Table 1











n (%) n (%) n (%) n (%)
Age
  <35 14 (2%) 5 (2%) 5 (2%) 11 (5%)
  35–44 90 (14%) 27 (13%) 32 (15%) 42 (20%)
  45–54 160 (25%) 59 (29%) 55 (26%) 44 (21%)
  55–64 163 (26%) 55 (27%) 60 (29%) 64 (31%)
  65–74 155 (24%) 51 (25%) 40 (19%) 39 (19%)
  75+ 51 (8%) 10 (5%) 16 (8%) 7 (3%)
BMI
  <25kg/m2 283 (45%) 94 (46%) 100 (49%) 85 (42%)
  25–30kg/m2 206 (33%) 78 (38%) 53 (26%) 74 (36%)
  30+kg/m2 136 (22%) 34 (17%) 50 (25%) 46 (22%)
  Missing 8 1 5 2
Income
  <$15,000–$24,999 125 (20%) 28 (14%) 40 (19%) 54 (26%)
  $25,000–$49,999 188 (30%) 66 (32%) 60 (29%) 59 (29%)
  $50,000-$90,000+ 318 (50%) 113 (55%) 107 (52%) 93 (45%)
  Missing 2 0 1 1
Education
  <HS-HS graduate 277 (44%) 89 (43%) 85 (41%) 99 (48%)
  Some college/-College graduate 253 (40%) 82 (40%) 93 (45%) 73 (36%)
  Post college 100 (16%) 36 (17%) 29 (14%) 33 (16%)
  Missing 3 0 1 2
Parity/Lactation history
  Nulliparous 67 (11%) 27 (13%) 17 (8%) 22 (11%)
  Parous/never lactated 350 (55%) 115 (56%) 108 (52%) 121 (58%)
  Parous/ever lactated 216 (34%) 65 (31%) 83 (40%) 64 (31%)
Menopausal status
  Premenopausal 212 (34%) 71 (35%) 78 (38%) 60 (30%)
  Postmenopausal 409 (66%) 133 (65%) 128 (62%) 140 (70%)
  Missing 12 3 2 7
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997 and 
followed-up through December 31, 2011.
a
Lipid-adjusted p,p’-DDT concentration cut-points: Tertile 1 (<56.8ng/g), Tertile 2 (≥56.8–<91.2ng/g), Tertile 3 (≥91.2ng/g)
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Table 4
Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between blood levels of 
organochlorines and mortality in the LIBCSP women diagnosed with breast cancer in 1996–1997 (n=558), 
stratified by adult-lifetime weight-gain.
0-<20% gain 15-Year All-Cause Mortality
Multivariable-Adjusteda
Deaths Censored HR (95% CI) p-trend
p,p’-DDTb
  Tertile 1 15 47 1 (Reference)
  Tertile 2 21 53 2.11 (1.03, 4.32)
  Tertile 3 15 53 0.81 (0.37, 1.75) 0.56
p,p’-DDEc
  Tertile 1 15 57 1 (Reference)
  Tertile 2 18 54 0.91 (0.43, 1.94)
  Tertile 3 18 45 0.92 (0.39, 2.16) 0.86
Chlordaned
  Tertile 1 12 56 1 (Reference)
  Tertile 2 17 39 1.55 (0.70, 3.41)
  Tertile 3 19 44 1.30 (0.58, 2.93) 0.22
20-<40% gain 15-Year All-Cause Mortality
Multivariable-Adjusteda
Deaths Censored HR (95% CI) p-trend
p,p’-DDTb
  Tertile 1 19 48 1 (Reference)
  Tertile 2 21 31 1.30 (0.67, 2.51)
  Tertile 3 25 45 0.98 (0.50, 1.90) 0.82
p,p’-DDEc
  Tertile 1 21 44 1 (Reference)
  Tertile 2 19 40 0.71 (0.37, 1.38)
  Tertile 3 26 40 0.49 (0.24, 0.99) 0.09
Chlordaned
  Tertile 1 15 39 1 (Reference)
  Tertile 2 28 40 1.34 (0.69, 2.60)
  Tertile 3 20 39 0.72 (0.34, 1.52) 0.23
≥40% gain 15-Year All-Cause Mortality
Multivariable-Adjusteda
Deaths Censored HR (95% CI) p-trend
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0-<20% gain 15-Year All-Cause Mortality
Multivariable-Adjusteda
Deaths Censored HR (95% CI) p-trend
p,p’-DDTb
  Tertile 1 17 41 1 (Reference)
  Tertile 2 20 32 1.11 (0.54, 2.25)
  Tertile 3 13 33 0.63 (0.28, 1.41) 0.68
p,p’-DDEc
  Tertile 1 11 32 1 (Reference)
  Tertile 2 16 42 0.95 (0.42, 2.15)
  Tertile 3 23 36 0.93 (0.40, 2.14) 0.40
Chlordaned
  Tertile 1 11 38 1 (Reference)
  Tertile 2 16 34 1.17 (0.50, 2.75)
  Tertile 3 19 32 1.01 (0.41, 2.50) 0.51
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997 and 
followed-up through December 31, 2011.
a
Adjusted for age at diagnosis, smoking status, income, body mass index and parity/lactation history
b
Lipid-adjusted p,p’-DDT concentration cut-points: Tertile 1 (<56.8ng/g), Tertile 2 (≥56.8–<91.2ng/g), Tertile 3 (≥91.2ng/g)
c
Lipid-adjusted p,p’-DDE concentration cut-points: Tertile 1 (<467.1ng/g), Tertile 2 (≥467.1–<1,058.2ng/g), Tertile 3 (≥1,058.2ng/g)
d
Lipid-adjusted chlordane (Σoxychlordane and trans-nonachlor) concentration cut-points: Tertile 1 (<81.1ng/g), Tertile 2 (≥81.1–<131.0ng/g), 
Tertile 3 (≥131.0ng/g)
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